![](https://static.wixstatic.com/media/11062b_6a134fc09ea34833a17d295e295ab517f000.jpg/v1/fill/w_1920,h_1080,al_c,q_90,enc_auto/11062b_6a134fc09ea34833a17d295e295ab517f000.jpg)
![](https://static.wixstatic.com/media/11bbf712d7d34ce69ac5afafb3fea993.jpg/v1/crop/x_0,y_362,w_1897,h_857/fill/w_920,h_437,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/11bbf712d7d34ce69ac5afafb3fea993.jpg)
Forging the Future
​ GRIN-X is the intersection for Genetics, Robotics, Information and Nanotechnology.
​
-
Futurists predict that in the near decade GRIN will completely transform the market space.
-
Never before imagined products, therapies, technologies and markets will emerge.
-
Conventional regulations, traditional financing, and corporate models will be disrupted.
​
Benefits
Via our corporate strategy and competitive intelligence services, we provide emerging technology pathfinders, key stake holders, and visionary investors, a road map to navigate the human and business terrain, to achieve successful emergence of new medicines, treatments and technology products.
Since 2014 every GRIN-X client exceeded goals. For example:
Cancer Prevention Pharmaceuticals - 2018
In April 2018, UK-based Mallinckrodt had exercised its option to the license agreement, and paid CPP $10 million to support the pivotal Phase 3 clinical trial of CPP-1X/sul in patients with the orphan disease familial adenomatous polyposis (FAP).
Calimmune - 2017
Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Calimmune, Inc., a biotechnology company focused on the development of ex vivo hematopoietic stem cell (HSC) gene therapy with R&D facilities in Pasadena, California and Sydney, Australia for an upfront payment of $91 million, with possible milestone payments reaching an eventual total of $416 million.
GRIN-X
520-241-7690
8987 E Tanque Verde Rd
St 309-245
Tucson, AZ 85749